Lates News

Every JJAI Express News, Dongwu Securities released a research report on April 27th, giving a "buy" rating to Yifang Biotechnology (688382.SH) with a target price of 39.03 yuan. The reasons for the rating mainly include: 1) D-2570: a highly selective TYK2 deformer inhibitor, with broad application prospects in the fields of PSO, PsA, UC, etc., tapping into the market of self-immunity; 2) D-0502: oral SERD highlights its clinical value in breast cancer, showing better safety and anti-tumor prospects compared to the fluorovinyl group as a single drug; 3) focusing on non-small cell lung cancer, two products, Befotinib & Goserelin, and Beta Pharmaceutical & Sinopharm Tianqing collaborated on sales, releasing commercial potential. (Daily Economic News)